Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Signs MOU to Mine High Grade Zone 2 at Cam Copper Mine (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Emerald Health Therapeutics Inc TBQBF


Primary Symbol: EMHTF

Healthcare Drug Manufacturers - Specialty & Generic Cannabis
Emerald is committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis products with an emphasis on innovation and production excellence.


OTCQB:EMHTF - Post by User

Emerald Health Therapeutics Inc
Bullboard Posts
User Avatar Image
(9)
•••
Comment by cannhealthon Apr 20, 2018 9:56am
177 Views
Post# 27916624

RE:Watch For Huge Insider Selling Over The Next 2 Months

RE:Watch For Huge Insider Selling Over The Next 2 Months
I'm quite pleased 51% of EHN has been rolled into EHT. Having VANC as a sales force for these products virtually ensures their sales will be contributing to 2nd Qtr 2018 EHT /EMH revenues. Regarding the siphoning of funds from Therapeutics to finance clinical trials of the Pharma division.. nonsense unless proven otherwise. Besides, the pharma and science entities have their own and separate funding sources.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested